#ASCO23 – 2023 ASCO Annual Meeting – Social Media Analytics and Transcripts
The 2023 ASCO Annual Meeting is your all-access pass to join global cancer experts and discover the latest innovations in cancer research and education.
Related Articles
Spoutible
Spoutible’s goal is to allow users to spout off while mitigating targeted harassment, threats of violence, racism, antisemitism, homophobia, transphobia, rampant misogyny, mis/disinformation, and platform…
Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for…
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials
Clinical Pharmacology & Therapeutics is a cross-disciplinary clinical medicine journal publishing advances in the nature, action, efficacy, and evaluation of therapeutics.
Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options – Tempus
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not…
Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone.
3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to false negatives. RNA-based,…
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications…
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined…
Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
This cross-sectional study examines the prevalence of germline findings in patients undergoing tumor/normal matched sequencing among cancer types lacking guidelines.
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO’s membership following publication or presentation of potentially practice-changing data from major studies. This…